Taken together these data highlight a correlation between cyclin D1/CDK4 expression and KRAS mutation in lung ADC, suggesting enhanced activation of CDK4/Cyclin D in KRAS mutant lung cancer. Here, CDK4 is linked to lung carcinoma.